article thumbnail

AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash

pharmaphorum

Qulipta (atogepant) is AbbVie’s second oral CGRP inhibitor after Ubrelvy (ubrogepant) – which was approved for the acute treatment of migraine attacks in 2019 – and rounds out a range that also includes the injectable Botox. Botox is prescribed for the prevention of headaches in adults diagnosed with chronic migraine.

Botox 52
article thumbnail

Latest ABPI code breaches reveal the risk of ‘likes’ on LinkedIn

pharmaphorum

Allergan fell foul of the regulations for a number of LinkedIn and Instagram posts promoting Botox (botulinum toxin type A) to the public by the chief executive of aesthetics clinic – described in his profile as an ‘Allergan mentee’, which were also liked or commented on by employees of the company.

Botox 63
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis’ Aimovig tops topiramate in migraine face-off

pharmaphorum

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial. The company has exclusive rights to the sell Aimovig outside the US, where Amgen records sales, with the exception of Japan.

Botox 89
article thumbnail

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

pharmaphorum

The decision is based on trials comparing Emgality with placebo which showed that the antibody halved the number of monthly migraine headache days for up to 40% of adults with migraine who had previously tried three or more prior medicines, such as Allergan’s Botox (botulinum toxin type A) or topiramate.

Sales 90
article thumbnail

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

pharmaphorum

The decision is based on trials comparing Emgality with placebo which showed that the antibody halved the number of monthly migraine headache days for up to 40% of adults with migraine who had previously tried three or more prior medicines, such as Allergan’s Botox (botulinum toxin type A) or topiramate.

Sales 86
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion in pharmaceutical sales from 2021. In contrast, several drugs experienced sale declines, such as Remicade (infliximab), an old immunology medication that continues to decline due to the rise of biosimilars since 2016.

Sales 98
article thumbnail

AbbVie Reports Second-Quarter 2021 Financial Results

The Pharma Data

AbbVie delivered another strong quarter and our business continues to perform extremely well across the portfolio, with AbbVie’s new immunology assets contributing more than $1 billion of combined sales in the quarter,” said Richard A. Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0

Botox 52